Download PDF
Thromb Haemost 2007; 97(01): 124-128
DOI: 10.1160/TH06-07-0381
Animal Models
Schattauer GmbH

Recombinant annexin-2 inhibits the progress of diabetic nephropathy in a diabetic mouse model via recovery of hypercoagulability

Hideto Ishii
1   Bioethics Research Centre, Tokyo Medical and Dental University, Tokyo, Japan
2   Department of Geriatrics and Vascular Medicine, School of Medicine, Tokyo Medical and Dental University, Tokyo, Japan
,
Megumi Hiraoka
3   Department of Medical Biochemistry, Graduate School of Medicine, Tokyo Medical and Dental University, Tokyo, Japan
,
Akira Tanaka
4   Kanto Gakuin University, Kanagawa, Japan
,
Kentaro Shimokado
2   Department of Geriatrics and Vascular Medicine, School of Medicine, Tokyo Medical and Dental University, Tokyo, Japan
,
Masayuki Yoshida
1   Bioethics Research Centre, Tokyo Medical and Dental University, Tokyo, Japan
2   Department of Geriatrics and Vascular Medicine, School of Medicine, Tokyo Medical and Dental University, Tokyo, Japan
3   Department of Medical Biochemistry, Graduate School of Medicine, Tokyo Medical and Dental University, Tokyo, Japan
› Author AffiliationsFinancial support: Funds from Ministry of Education, Science, Sports and Culture of Japan and special coordination funds from the Science and Technology Agency of Japan.
Further Information

Publication History

Received 11 July 2006

Accepted after resubmission 20 November 2006

Publication Date:
28 November 2017 (online)

    Permissions and Reprints

Summary

Diabetic nephropathy, a major complication of diabetes mellitus that leads to mortality, has been shown to involve a dysregulation of the coagulation system. Annexin-2, a co-receptor for plasminogen and tissue plasminogen activator on endothelial cells, is one of the molecules required to maintain the antithrombogenic properties of endothelial cells. Previously, we showed that recombinant annexin-2 protein (rAN II) modulated impaired fibrinolytic activity in the carotid arteries of rats. In the present study, to investigate its protective effects against diabetic nephropathy, rAN II was administered to KK-Ay mice, a murine model of type 2 diabetes, for eight weeks, and albuminuria, kidney size, and histological glomerular lesions were investigated. The mean weight of kidneys from KK-Ay mice treated with rAN II was significantly less than that of those treated with PBS (control) (p<0.02). Furthermore, the level of albuminuria observed in rAN II-treated KK-Ay mice was significantly less than that of the control group (rAN II, 0.90+/-0.12 µg/day; PBS, 1.55+/-0.31 µg/day; p<0.01); also, the area of diffuse glomerular lesions was significantly smaller (rAN II, 41.51+/-4.54%; PBS, 81.81+/-8.10%; p<0.01). Bleeding time, prothrombin time (PT), and active partial thromboplastin time (APTT) did not significantly differ between the two groups. Our results suggest that rAN II may inhibit the progression of diabetic nephropathy in KK-Ay mice without influencing the coagulation system, indicating that annexin-2 may be considered as a possible new therapeutic tool for patients with diabetic nephropathy.

Keywords

Annexins - hypercoagulability - endothelial cells - diabetes mellitus
 

  • References

  • 1 The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329: 977-86.
    CrossrefPubMedGoogle Scholar
  • 2 Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837-53.
    CrossrefPubMedGoogle Scholar
  • 3 Bergstrom J. Discovery and rediscovery of low protein diet. Clin Nephrol 1984; 21: 29-35.
    PubMedGoogle Scholar
  • 4 Parving HH, Smidt UM, Hommel E. et al Effect of antihypertensive treatment on kidney function in diabetic nephropathy. Br Med J (Clin Res Ed) 1987; 294: 1443-7.
    CrossrefPubMedGoogle Scholar
  • 5 Vukovich T, Knobl P, Teufelsbauer H. et al The effect of insulin treatment on the balance between tissue plasminogen activator and plasminogen activator inhibitor-1 in type 2 diabetic patients. Thromb Haemost 1992; 68: 253-6.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Roshan B, Weinrauch LA, Gleason RE. et al Improved glycemic control and platelet function abnormalities in diabetic patients with microvascular disease. Metabolism 2000; 49: 88-91.
    CrossrefPubMedGoogle Scholar
  • 7 Raynal P. Annexins: the problem of assessing the biological role for a gene family of multifunctional calcium-and phospholipid-binding proteins. Biochim Biophys Acta 1994; 1197: 63-93.
    CrossrefPubMedGoogle Scholar
  • 8 Swairjo MA. Annexin structure and membrane interactions: a molecular perspective. Annu Rev Biophys Biomol Struct 1994; 23: 193-213.
    CrossrefPubMedGoogle Scholar
  • 9 Hajjar KA. The endothelial cell tissue plasminogen activator receptor. Specific interaction with plasminogen. J Biol Chem 1991; 266: 21962-70.
    CrossrefPubMedGoogle Scholar
  • 10 Hajjar KA, Chacko J. An endothelial cell receptor for plasminogen/tissue plasminogen activator. I. Identity with annexin II. J Biol Chem 1994; 269: 21191-7.
    CrossrefPubMedGoogle Scholar
  • 11 Ishii H, Hiraoka M, Hajjar KA. et al Recombinant annexin II modulates impaired fibrinolytic activity in vitro and in rat carotid artery. Circ Res 2001; 89: 1240-5.
    CrossrefPubMedGoogle Scholar
  • 12 Nakamura M. A diabetic strain of the mouse. Proc Jap Acad 1962; 38: 384-52.
    CrossrefPubMedGoogle Scholar
  • 13 Nishimura M. Breeding of mice strains for diabetes mellitus. Exp Anim 1969; 18: 147-57.
    CrossrefPubMedGoogle Scholar
  • 14 Iwatsuka H, Matsuo T, Suzuoki Z. Congenitally impaired hormone sensitivity of the adipose tissue of spontaneously diabetic mice, KK. Validity of thrifty genotype in KK mice. Diabetologia 1974; Suppl 611-6.
    CrossrefPubMedGoogle Scholar
  • 15 Iwatsuka H, Suzuoki Z. General survey of diabetic features of yellow KK mice. Endocrinol Jpn 1970; 17: 23-35.
    CrossrefPubMedGoogle Scholar
  • 16 Seyer-Hansen K. Renal hypertrophy in streptozotocin diabetic rats. Clin Sci Molec Med 1976; 51: 551-5.
    PubMedGoogle Scholar
  • 17 Cortes P, Goldman J, Levin NW. Relationship between renal function and metabolic alterations in early streptozocin-induced diabetes in rats. Diabetes 1987; 36: 80-7.
    CrossrefPubMedGoogle Scholar
  • 18 Muto Y, Muto G, Masuda T. et al Effect of longterm treatment with complete Freund’s adjuvant on KK-Ay mouse, a model of non-insulin-dependent diabetes mellitus. Clin Immunol Immunopathol 1997; 83: 53-9.
    CrossrefPubMedGoogle Scholar
  • 19 Hajjar KA. Identification and characterization of human endothelial cell membrane binding sites for tissue plasminogen activator and urokinase. J Biol Chem 1990; 265: 2908-16.
    CrossrefPubMedGoogle Scholar
  • 20 Kurz KD, Sandusky GE.. Rat model of arterial thrombosis induced by ferric chloride. Thromb Res 1990; 60: 269-80.
    CrossrefPubMedGoogle Scholar
  • 22 Guthrow CE, Day JF, Thorpe SR. et al Enhanced nonenzymatic glucosylation of human serum albumin in diabetes mellitus. Proc Natl Acad Sci USA 1979; 76: 4258-61.
    CrossrefPubMedGoogle Scholar
  • 22 Cohen MP, Surma M, Ciborowski CJ. Nonenzymatic glycosylation of basement membranes: in vitro studies. Diabetes 1981; 30: 367-71.
    CrossrefPubMedGoogle Scholar
  • 23 Williams SK, Bitensky MW. Micropinocytic ingestion of glycosylated albumin by isolated microvessels: possible role in pathogenesis of diabetic microangiopathy. Proc Natl Acad Sci USA 1981; 78: 2393-7.
    CrossrefPubMedGoogle Scholar